Telix Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	803.79	516.55	332.98	108.95	5.52
Revenue Growth (YoY)	55.61%	55.13%	205.64%	1873.25%	37.53%
Cost of Revenue	377.36	180.39	123.45	44.35	1.85
Gross Profit	426.44	336.16	209.53	64.6	3.67
Selling, General & Admin	237.15	157.94	89.38	59.49	12.27
Research & Development	171.25	127.93	85.32	54.91	24.81
Other Operating Expenses	-11.74	-4.89	23.83	12.76	-
Total Operating Expenses	396.66	280.99	198.53	127.16	37.08
Operating Income	29.78	55.18	11.01	-62.56	-33.41
Interest Income	5.83	7.18	0.67	0	-
Interest Expense	-40.87	-24.44	-9.09	-4.55	-3.79
Total Non-Operating Income (Expense)	-35.04	-17.26	-8.41	-4.55	-3.79
Pretax Income	-5.27	37.92	2.59	-67.11	-58.49
Provision for Income Taxes	1.86	4.23	-1.61	3.71	0.03
Net Income	-7.13	33.69	4.21	-70.83	-58.52
Net Income to Common	-7.13	33.69	4.21	-70.83	-58.52
Net Income Growth	-	700.50%	-	-	-
Shares Outstanding (Basic)	338	331	319	311	282
Shares Outstanding (Diluted)	338	345	324	311	282
Shares Change (YoY)	-2.12%	6.64%	4.21%	10.08%	9.69%
EPS (Basic)	-0.02	0.10	0.01	-0.23	-0.21
EPS (Diluted)	-0.02	0.10	0.01	-0.23	-0.21
EPS Growth	-	650.77%	-	-	-
Free Cash Flow	-60.28	45.86	22.24	-48.32	-44.1
Free Cash Flow Growth	-	106.23%	-	-	-
Free Cash Flow Per Share	-0.18	0.13	0.07	-0.16	-0.16
Gross Margin	53.05%	65.08%	62.93%	59.29%	66.46%
Operating Margin	3.70%	10.68%	3.31%	-57.42%	-605.17%
Profit Margin	-0.89%	6.52%	1.26%	-65.01%	-1059.90%
FCF Margin	-7.50%	8.88%	6.68%	-44.35%	-798.67%
EBITDA	51.19	60.46	15.16	-58.9	-29.65
EBITDA Margin	6.37%	11.70%	4.55%	-54.06%	-537.06%
EBIT	29.78	55.18	11.01	-62.56	-33.41
EBIT Margin	3.70%	10.68%	3.31%	-57.42%	-605.17%
Effective Tax Rate	-35.30%	11.16%	-62.22%	-5.53%	-0.06%

SEC Filings: 10-K · 10-Q